Improving Engraftment, Islet Survival and Metabolic Reserve in Clinical Islet Transplantation Using Caspase Inhibitor - IDN-6556
Phase of Trial: Phase I/II
Latest Information Update: 11 Jul 2016
At a glance
- Drugs Emricasan (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 05 Jul 2016 Status changed from active, no longer recruiting to completed.
- 01 Dec 2015 Planned End Date changed from 1 Jun 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.